Spectrum Pharmaceuticals (NASDAQ:SPPI) had its target price upped by HC Wainwright to $33.00 in a research report report published on Monday morning. They currently have a buy rating on the biotechnology company’s stock.

Several other equities analysts have also recently issued reports on SPPI. BidaskClub cut Spectrum Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Saturday, February 3rd. B. Riley began coverage on Spectrum Pharmaceuticals in a research note on Monday, December 18th. They set a buy rating and a $26.00 target price on the stock. Jefferies Group boosted their target price on Spectrum Pharmaceuticals from $13.00 to $18.00 and gave the company a buy rating in a research note on Monday, October 9th. Zacks Investment Research raised Spectrum Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, January 12th. Finally, Guggenheim began coverage on Spectrum Pharmaceuticals in a research note on Monday, October 23rd. They set a buy rating and a $32.00 target price on the stock. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $22.83.

Spectrum Pharmaceuticals (SPPI) opened at $20.73 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.89 and a current ratio of 5.04. Spectrum Pharmaceuticals has a 12 month low of $4.86 and a 12 month high of $23.50. The stock has a market capitalization of $2,090.00, a P/E ratio of -20.73 and a beta of 1.64.

Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in Spectrum Pharmaceuticals in the third quarter worth $152,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Spectrum Pharmaceuticals in the third quarter worth $177,000. Campbell & CO Investment Adviser LLC purchased a new stake in Spectrum Pharmaceuticals in the third quarter worth $192,000. Crossmark Global Holdings Inc. purchased a new stake in Spectrum Pharmaceuticals in the third quarter worth $212,000. Finally, Piedmont Investment Advisors LLC purchased a new stake in Spectrum Pharmaceuticals in the second quarter worth $114,000. 71.77% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Spectrum Pharmaceuticals (SPPI) PT Raised to $33.00” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/spectrum-pharmaceuticals-sppi-pt-raised-to-33-00/1851760.html.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Analyst Recommendations for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.